|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,500,000 |
Market
Cap: |
40.27(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.41 - $4.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cue Biopharma is a biopharmaceutical company engineering a class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body. Co. is focusing on drug product candidates for treating cancer in its CUE-100 series, which exploits rationally engineered interleukin 2, in context of the key Immuno- Selective Targeting and Alteration of T Cells framework for selective activation of targeted tumor-specific T cells. Co. is seeking third party support through partnerships and collaborations, or alternative funding structures, to further develop its programs outside of oncology, including its CUE-200, CUE-300 and CUE-400 series.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
7,000 |
240,000 |
Total Buy Value |
$0 |
$0 |
$19,620 |
$836,320 |
Total People Bought |
0 |
0 |
2 |
4 |
Total Buy Transactions |
0 |
0 |
2 |
5 |
Total Shares Sold |
0 |
0 |
0 |
9,325 |
Total Sell Value |
$0 |
$0 |
$0 |
$30,586 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Suri Anish |
PRESIDENT AND CSO |
|
2023-08-25 |
4 |
B |
$2.76 |
$11,040 |
D/D |
4,000 |
135,638 |
2.74 |
-4% |
|
Passeri Daniel R |
CHIEF EXECUTIVE OFFICER |
|
2023-08-14 |
4 |
B |
$2.86 |
$8,580 |
D/D |
3,000 |
134,578 |
2.81 |
-11% |
|
Verheyen Patrick |
Director |
|
2023-04-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,174 |
|
-4% |
|
Kiener Peter A |
Director |
|
2023-03-23 |
4 |
S |
$3.28 |
$30,586 |
D/D |
(9,325) |
357 |
|
-11% |
|
Kiener Peter A |
Director |
|
2023-03-23 |
4 |
OE |
$2.86 |
$27,691 |
D/D |
9,682 |
9,682 |
|
- |
|
Levisetti Matteo |
Chief Medical OfficerOfficer |
|
2023-01-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,230 |
|
18% |
|
Millar Kerri-Ann |
CHIEF FINANCIAL OFFICER |
|
2022-08-22 |
4 |
D |
$3.05 |
$8,625 |
D/D |
(2,828) |
14,311 |
|
- |
|
Millar Kerri-Ann |
CHIEF FINANCIAL OFFICER |
|
2022-08-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
17,139 |
|
- |
|
Gray Cameron |
Director |
|
2022-06-14 |
4 |
D |
$3.20 |
$164,998 |
D/D |
(51,562) |
687,049 |
|
- |
|
Gray Cameron |
Director |
|
2022-06-14 |
4 |
OE |
$2.70 |
$165,000 |
D/D |
61,111 |
738,611 |
|
- |
|
Morich Frank |
Director |
|
2022-05-27 |
4 |
B |
$3.75 |
$105,000 |
D/D |
28,000 |
28,000 |
2.39 |
-21% |
|
Fletcher Aaron G.l. |
Director |
|
2022-05-24 |
4 |
B |
$3.34 |
$183,700 |
I/I |
55,000 |
940,000 |
2.1 |
-7% |
|
Fletcher Aaron G.l. |
Director |
|
2022-05-23 |
4 |
B |
$3.52 |
$528,000 |
I/I |
150,000 |
885,000 |
2.1 |
-33% |
|
Suri Anish |
PRESIDENT AND CSO |
|
2022-03-31 |
4 |
D |
$4.88 |
$34,492 |
D/D |
(7,068) |
103,638 |
|
- |
|
Suri Anish |
PRESIDENT AND CSO |
|
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,668 |
110,706 |
|
- |
|
Fletcher Aaron G.l. |
Director |
|
2022-03-31 |
4 |
B |
$4.76 |
$3,498,600 |
I/I |
735,000 |
735,000 |
2.1 |
-34% |
|
Passeri Daniel R |
CHIEF EXECUTIVE OFFICER |
|
2022-03-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
131,578 |
|
- |
|
Passeri Daniel R |
CHIEF EXECUTIVE OFFICER |
|
2022-03-31 |
4 |
D |
$4.88 |
$156,755 |
D/D |
(32,122) |
141,578 |
|
- |
|
Passeri Daniel R |
CHIEF EXECUTIVE OFFICER |
|
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
173,700 |
|
- |
|
Kiener Peter A |
Director |
|
2021-11-16 |
4 |
AS |
$18.02 |
$24,525 |
D/D |
(1,361) |
0 |
|
-73% |
|
Kiener Peter A |
Director |
|
2021-11-16 |
4 |
OE |
$2.86 |
$3,892 |
D/D |
1,361 |
1,361 |
|
- |
|
Kiener Peter A |
Director |
|
2021-11-15 |
4 |
AS |
$17.92 |
$337,165 |
D/D |
(18,815) |
0 |
|
-72% |
|
Kiener Peter A |
Director |
|
2021-11-15 |
4 |
OE |
$2.86 |
$53,811 |
D/D |
18,815 |
18,815 |
|
- |
|
Suri Anish |
President and CSO |
|
2021-11-15 |
4 |
AS |
$18.05 |
$144,400 |
D/D |
(8,000) |
94,038 |
|
-72% |
|
Suri Anish |
President and CSO |
|
2021-11-15 |
4 |
OE |
$8.26 |
$66,080 |
D/D |
8,000 |
102,038 |
|
- |
|
112 Records found
|
|
Page 1 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|